晨光生物(300138) - 2026 Q1 - 季度业绩预告

Financial Projections - The estimated net profit for Q1 2026 is projected to be between 90 million and 115 million CNY, representing a year-on-year change of -17.79% to 5.04%[5] - The net profit after deducting non-recurring gains and losses is expected to be between 83 million and 108 million CNY, with a year-on-year change of -13.47% to 12.59%[5] - The impact of non-recurring gains and losses is estimated to be approximately 7 million CNY[6] - The specific financial data for Q1 2026 will be detailed in the company's quarterly report[7] Business Development - The company has experienced stable business development, leveraging inventory purchased in the previous year and actively adjusting sales strategies[6] - The subsidiary in Zambia faced increased product costs due to natural disasters last year, which continued to affect gross margins in the current reporting period[6]